What are the recommended birth control options for a female patient of childbearing age with a history of migraines with aura?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Migraine with Aura Birth Control Recommendations

Women with migraine with aura must avoid all combined hormonal contraceptives (pills, patches, rings) and should use progestin-only methods instead, as combined hormonal contraceptives increase stroke risk 7-fold in this population. 1

Absolutely Contraindicated Methods

Combined hormonal contraceptives are completely prohibited in migraine with aura due to multiplicative stroke risk:

  • Combined oral contraceptives, patches, and vaginal rings are contraindicated regardless of age, as they increase ischemic stroke risk 7-fold (RR 7.02; 95% CI 1.51-32.68) compared to non-users 1
  • The risk is particularly severe in women under age 45 (RR 3.65; 95% CI 2.21-6.04) 1
  • Smoking amplifies this risk catastrophically (RR 9.03; 95% CI 4.22-19.34), making tobacco use an absolute contraindication if any hormonal contraception is considered 1
  • The absolute risk translates to approximately 4 additional intracranial hemorrhage events per 10,000 women per year 1
  • The American Heart Association/American Stroke Association explicitly recommends against estrogen-containing contraceptives in individuals with migraine with aura 2

First-Line Recommended Option: Progestin-Only Pills

Progestin-only pills (POPs) are the preferred first-line contraceptive for migraine with aura, classified as Category 1 (no restrictions) by the CDC:

  • Norethindrone-containing POPs carry no increased stroke risk and may actually reduce migraine frequency 1
  • These pills do not alter coagulation or exacerbate migraine like combined hormonal contraceptives 3
  • The most common side effect is irregular bleeding, which is not harmful but requires patient counseling 1
  • Avoid drospirenone-containing POPs only in patients with hyperkalemia 1
  • Research demonstrates that desogestrel 75 mcg/day POP significantly reduces migraine attacks, migraine days, intensity, duration, and analgesic use while improving quality of life 4

Second-Line Safe Alternatives

Long-acting progestin methods provide excellent alternatives when daily pill adherence is challenging:

Depot Medroxyprogesterone Acetate (DMPA) Injections

  • Classified as Category 2 (advantages generally outweigh risks) for migraine with aura 1
  • Lasts 11-13 weeks, eliminating daily adherence requirements 1
  • May reduce migraine frequency and cause amenorrhea with continued use 1
  • Initial irregular bleeding typically resolves before achieving amenorrhea 1

Levonorgestrel Intrauterine Device (LNG-IUD)

  • Excellent option that avoids systemic estrogen while managing menstrual irregularities 1
  • Provides 3-5 years of contraception depending on formulation 1

Etonogestrel Implant

  • Safe for women with migraine with aura and provides 3 years of contraception 1
  • Single-rod subdermal implant with minimal systemic progestin exposure 5

Non-Hormonal Option

Copper intrauterine device (IUD) is completely safe:

  • Carries zero stroke risk as it contains no hormones 6
  • Provides 10 years of highly effective contraception 6
  • May worsen dysmenorrhea and menstrual bleeding, which could be problematic if menstrual migraine is present 6

Critical Risk Factor Assessment

Before prescribing any contraception, evaluate and eliminate additional stroke risk factors:

  • Tobacco use: Absolutely prohibit smoking, as it creates catastrophic stroke risk when combined with migraine with aura 1
  • Hypertension: Screen for and aggressively manage elevated blood pressure 1
  • Thrombophilia: Evaluate for inherited clotting disorders before initiating any hormonal method 7
  • Diabetes and hyperlipidemia: Screen for metabolic risk factors that compound stroke risk 1
  • Age over 35: Increases baseline stroke risk, making progestin-only methods even more critical 1

Special Clinical Scenarios

If Patient Previously Used Combined Hormonal Contraceptives

  • Switch immediately to progestin-only methods as it is reasonable to advise individuals with migraine and prior stroke risk who are taking oral contraceptives to change to another form of birth control 3

If Migraine Frequency is High (>Weekly)

  • High migraine frequency with aura further amplifies ischemic stroke risk (HR 4.25; 95% CI 1.36-13.29) 2
  • Consider adding migraine prophylaxis (propranolol 80-160 mg daily or topiramate 50-100 mg daily) alongside progestin-only contraception 8

If Patient Has Migraine Without Aura

  • Age <35 years without additional risk factors: Combined hormonal contraceptives classified as Category 2 (generally safe) 1
  • Age ≥35 years: Combined hormonal contraceptives classified as Category 3 (risks usually outweigh benefits); strongly prefer progestin-only methods 1

Common Pitfalls to Avoid

  • Do not assume all migraines are the same: Migraine with aura carries dramatically higher stroke risk than migraine without aura when combined with estrogen 3
  • Do not prescribe "low-dose" combined hormonal contraceptives thinking they are safer: Even modern low-dose formulations remain contraindicated in migraine with aura 9
  • Do not overlook smoking status: This single factor can increase stroke risk 9-fold when combined with migraine and estrogen 1
  • Do not dismiss irregular bleeding as a contraindication: Irregular bleeding with progestin-only methods is not harmful and typically improves with continued use 1

References

Guideline

Contraceptive Options for Women with Migraine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Gender-Affirming Estrogen Therapy in Migraine with Aura

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Oral contraceptives in migraine.

Expert review of neurotherapeutics, 2009

Guideline

Dysmenorrhea Treatment Options in Women with Migraine with Aura

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Combined hormonal contraception and migraine: are we being too strict?

Current opinion in obstetrics & gynecology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.